

17 November 2022

ASX Code: MXC

LSE Code: MXC

AGM Webcast

MGC Pharmaceuticals Limited ('MGC Pharma' or 'the Company') a European based bio-pharma company specialising in the production and development of plant inspired medicines, is pleased to announce that the board will be webcasting the Company's upcoming Annual General Meeting (AGM) to be held at 5:00pm AWST on the 24th of November 2022 via the Investor Meet Company platform.

In order to ensure that shareholders are able to follow the proceedings of the AGM without attending in person, the Company will provide access online via the Investor Meet Company platform. However, please note that shareholders will not be able to vote online at the AGM via the platform, and are therefore encouraged to submit their votes via proxy, per the instructions in the Notice of Meeting.

Questions can be pre submitted ahead of the AGM via the Investor Meet Company Platform, up until 5:00pm the day before the AGM or submitted at any time during the AGM itself.

Investors can sign up to Investor Meet Company for free and follow MGC Pharmaceuticals Ltd via: <https://www.investormeetcompany.com/mgc-pharmaceuticals-limited/register-investor>

Investors who already follow MGC Pharmaceuticals Ltd on the Investor Meet Company platform will automatically be invited to the AGM webcast.

--Ends--

Authorised for release by the Company Secretary, for further information please contact:

MGC Pharmaceuticals Ltd

Roby Zomer
CEO & Managing Director
+61 8 6382 3390
info@mgcpharma.com.au

UK Financial and Corporate Advisor

Hannam & Partners
Rupert Fane / Nilesh Patel
+44 7810 056 104
rf@hannam.partners / nilesh@hannam.partners

UK PR Advisors

Tavistock
Charles Vivian / Tim Pearson
+44 207 920 3150
mgcpharma@tavistock.co.uk

MGC Pharmaceuticals Ltd

David Lim
Company Secretary
+61 8 6382 3390
info@mgcpharma.com.au

UK Broker

Turner Pope
Andy Thacker
+44 203 657 0050
info@turnerpope.com

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company, focused on developing and supplying accessible and ethically produced plant inspired medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions.

The Company's founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high quality plant inspired medicines for the growing demand in the medical markets in Europe, North America and Australasia.

MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development.

MGC Pharma has partnered with renowned institutions and academia to optimise the development of targeted plant inspired medicines, to be produced in the Company's EU-GMP Certified manufacturing facilities.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels    